Imaging Study of Lithium Response in Bipolar Disorder

Principal Investigator: Pamela Mahon, Ph.D. (IRB NA_00049892)

Enrollment for this study is closed.

For more information about participation in future studies, please call 410-614-1017.

The primary objective of this study was to identify brain features that are associated with treatment response to lithium. 

Bipolar disorder is a serious mental illness. The treatment of choice for this disorder is the mood stabilizer lithium. However, responses vary greatly between patients with similar symptoms. While lithium is effective for some patients, others receive little benefit from lithium, and instead need to take other mood stabilizers. Unfortunately, there are limited predictors to guide physicians in medication selections and many patients need weeks or even months of trial-and-error approach. Some of our other studies have taken a genetics approach to finding possible predictors of lithium response. This study took an imaging approach to look for predictors of lithium response in brain structures.

GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering from a Major Depressive Disorder (MDD)

Principal Investigator: Peter Zandi, MPH, MHS, PhD; IRB00034264

Enrollment is now closed.

For more information about participation in future studies, please call 410-614-1017.

This study was a randomized, multicenter, doubleblind, 12-week, controlled study in parallel balanced groups of depressed patients. The study evaluated the impact of GeneSight Psychotropic on response to psychotropic treatments. Patients enrolled in this study were required to have a Diagnostic and Statistical Manual of Mental Disorders diagnosis of MDD, and an inadequate response within the current episode to one or more psychotropic treatments. Upon completion of the double-blind part of the study, participants continued in a 12-week open-label extension of the study to evaluate the long-term impact of the use of GeneSight Psychotropic. Data Analysis is currently underway.